How Much Does Januvia Cost in 2026, and Is the Generic Worth It?

Januvia (sitagliptin) is a once-daily oral tablet used to lower blood sugar in adults with type 2 diabetes. It works by blocking the DPP-4 enzyme, which allows the body's natural incretin hormones to remain active longer after a meal. Merck launched Januvia in 2006, and it became one of the top-selling diabetes drugs in the US. Its list price climbed steadily for nearly two decades, reaching over $527 per month before two simultaneous forces pushed costs down in 2026: the IRA Medicare negotiation and the arrival of generic competition.

On January 1, 2026, the IRA Maximum Fair Price of $113 per month took effect for Medicare Part D enrollees. Then in May 2026, generic sitagliptin from multiple manufacturers began entering US pharmacies under patent settlement agreements Merck reached with more than 25 generic companies. These settlements were not a gift: Merck's primary composition patent on sitagliptin phosphate does not expire until November 24, 2026, so each manufacturer paid a negotiated entry fee for the right to launch early. But the practical result for patients is that a generic alternative to Januvia is now physically available at most major pharmacy chains.

This page covers 2026 pricing for brand Januvia and generic sitagliptin by pharmacy, the IRA negotiated Medicare price, the Merck Helps patient assistance program with its income eligibility table, and what Medicaid and Part D enrollees should expect to pay. If you received a bill for Januvia or sitagliptin during a hospital stay, see the billing errors section. Oral diabetes medications are frequently overcharged in facility billing, even when the patient's own supply was used. Patients who can qualify for Medicaid typically pay $1 to $4 per prescription. Diabetic patients combining Januvia with metformin should check their plan's combined formulary tier. Farxiga and Jardiance are common alternatives in the same diabetes treatment ladder.

What Januvia Costs by Point of Pay (2026)

The price you pay depends almost entirely on WHERE you pay. The same januvia can cost many times more at a hospital than at your local pharmacy:

Why Hospitals Charge So Much

When a patient is admitted to a hospital and their home medications are continued during the stay, the hospital dispenses those drugs from its own pharmacy. The charge on your bill reflects a facility rate: the drug acquisition cost plus a markup for hospital pharmacy staff, dispensing systems, storage, and overhead. For an oral tablet like sitagliptin that costs under $5 to acquire in 2026, the facility charge can reach $15 to $30 per tablet, or $450 to $900 for a 30-day supply issued during a week-long admission.

This is not a billing error in the traditional sense. Hospitals are permitted to charge facility rates. But it can produce sticker shock for patients who were paying $60 to $120 per month for generic sitagliptin at their local pharmacy. The CMS Hospital Price Transparency rule (effective 2021) requires hospitals to publish their standard charges, so you have the right to compare your hospital's sitagliptin charge against their published rate file. If you brought your own medication from home and the hospital still billed you for dispensing it, that is a disputable charge.

A key distinction: Januvia is a Part D drug, not a Part B drug. In an outpatient setting, Medicare does not pay Part B rates for sitagliptin, and there is no published ASP rate for it. Coverage runs through Part D, subject to plan formulary and the 2026 $2,100 annual out-of-pocket cap. For inpatient stays, drug costs are bundled into the DRG payment. The hospital absorbs those costs from Medicare, but may still pass sitagliptin charges along on the patient's itemized bill. Ask for a line-item breakdown and verify dates of service match your actual admission window.

Patient Assistance Programs

Merck runs a patient assistance program for Januvia that provides the medication free of charge to qualifying uninsured patients. Eligibility requires a valid US prescription, no insurance coverage for the drug, and household income at or below 400% of the federal poverty level. Patients with insurance who face documented financial hardship may also apply. Separately, the availability of generic sitagliptin at $60 to $120 per month means most patients now have a low-cost alternative even without a formal PAP:

Medicare Part D

Januvia (sitagliptin) is a Part D drug. It is dispensed at the pharmacy and covered under Medicare prescription drug plans, not Part B. As of January 1, 2026, the IRA-negotiated Maximum Fair Price for Januvia is $113 per 30-day supply for any Medicare Part D enrollee. This applies regardless of plan formulary tier. No Part D plan may charge an enrollee more than $113 for brand Januvia at an in-network pharmacy. Patients who switch to generic sitagliptin through Part D will typically pay less than $113, as plan formularies often place generics in lower cost-sharing tiers.

The 2026 Part D out-of-pocket cap also applies to Januvia: once a patient has paid $2,100 total in Part D costs during a calendar year, cost share drops to $0 for the remainder of the year. At the $113 MFP, a patient paying exclusively for Januvia would take about 19 months to reach that cap, meaning the cap provides more tangible protection when multiple expensive drugs are involved. There is no separate insulin-style $35/month cap for Januvia; the IRA's $35 insulin cap applies only to insulin products, not to other diabetes drugs.

Common Januvia Billing Errors

Januvia and generic sitagliptin are oral tablets with no HCPCS J-code. They are not billed as infusions or injections. Still, several billing errors appear on hospital and outpatient claims for this drug:

• Billed at brand Januvia price when generic sitagliptin was actually dispensed: check the dispensed drug name and NDC number on your itemized bill; the generic and brand have different NDC codes
• Facility charge applied to medication the patient brought from home: hospitals cannot bill for drugs you self-supplied if those drugs were not dispensed from the hospital pharmacy
• Inpatient pharmacy rate applied after discharge date: charges for sitagliptin that appear after your discharge date may indicate billing for an outpatient fill at inpatient rates; check the date of service on each line
• Medicare Part D Maximum Fair Price not honored: if you are enrolled in Part D and were charged more than $113 for brand Januvia in 2026, contact your plan's member services and file a coverage determination request
• Combination product billed instead of sitagliptin alone: Janumet (sitagliptin plus metformin) and Janumet XR carry a higher price and different formulary tier than sitagliptin alone; verify the dispensed product exactly matches the prescription

Frequently Asked Questions